BERG, Sanofi Pasteur Team Up to Assess Potential Biomarkers of Seasonal Influenza Vaccination Outcomes

BERG is working with Sanofi Pasteur, the influenza vaccine global leader, to generate and model data using BERG’s Interrogative Biology® platform to assess potential biomarkers of seasonal influenza vaccination outcomes in an unbiased and data-driven manner.

 

BERG, Parkinson’s Institute Focusing on Identifying Potential Biomarkers

BERG and the Parkinson’s Institute and Clinical Center have entered into a partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson’s disease.The partnership is the first to approach biomarker discovery by looking at proteomics, metabolomics, and lipidomics, in addition to clinical data, simultaneously in human patients and controls from the same cohort.

The partnership is the first to approach biomarker discovery by looking at proteomics, metabolomics, and lipidomics, in addition to clinical data, simultaneously in human patients and controls from the same cohort.

 

BERG Teams with Icahn School to Develop Potential Therapeutics for Cancer, Other Diseases

BERG and the Icahn School of Medicine at Mount Sinai have engaged in a research and development partnership to to obtain novel insights and potential therapeutics for cancer, central nervous system and endocrine disorders.

The partnership will leverage BERG’s Interrogative Biology® platform in combination with Mount Sinai’s expertise in big data, advanced analytics and biological network modeling.

 

BERG, Genomics England Aim to Accelerate Development of New Diagnostics, Treatments

BERG has partnered with Genomics England in it’s ambitious 100,000 genomes project which aims to accelerate development of new diagnostics and treatments. The project focuses on patients with rare diseases and six common cancers.The BERG Interrogative Biology® Platform will allow the program to look beyond the genome and gain a more robust understanding of the cellular activity of diseases.

 

BERG, DoD Using AI Platform to Ready Diagnostic Test for Prostate Cancer

CPDR is a comprehensive research program to study prostate cancer and prostate disease.

BD Taps BERG’s AI Platform to Reduce Medication Non-Adherence

BD (Becton, Dickinson and Company) a leader in medical technology, will use BERG‘s artificial intelligence platform to improve patient health by minimizing challenges associated with medication adherence for patients. The partnership will leverage BD’s healthcare IT expertise and BERG’s AI platform to develop a medication adherence algorithm that will help healthcare workers identify certain patient populations that are at the highest risk for nonadherence post-discharge.

Read More

BERG Forms Research Collaboration with AstraZeneca

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with
AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.